Ever since former Commissioner for Research Philippe Busquin established the European Cancer Research Area (ECRA) in 2002 (http://europa.eu/rapid/press-re lease_SPEECH-02-408_en.htm) to address the fragmentation of cancer research in Europe, the cancer community and policymakers have been trying to develop strategies to bridge the gaps between basic/ preclinical and clinical research and research and healthcare (Celis and Pavalkis, 2017) . These efforts culminated in 2014 with the creation of Cancer Core Europe (Eggermont et al., 2019) , a patient-centred legal structure on therapeutics that currently consists of seven large cancer centres (mainly Comprehensive Cancer Centres (CCCs, institutions that link research with the healthcare system; Saghatchian et al., 2008) across Europe. Inspired by the Cancer Core Europe initiative, a consortium of 10 cancer prevention centres was recently established -Cancer Prevention Europeto reinforce the complete cancer prevention research continuum (Wild et al., 2019) . At present, Cancer Core Europe and Cancer Prevention Europe are in the process of integrating their strategies to create a coherent plan for prevention, early detection and treatment, and efforts are underway to engage the outcomes research geometry and to network with other infrastructures, CCCs, and research and clinical centres across Europe (https://febs.onlinelibrary.wiley.com/toc/18780261/2019/ 13/3).
To date, several prominent scientific cancer organisations and cancer centres are collaborating to develop a unified insight towards a mission-oriented approach to cancer. These include Cancer Core Europe, Cancer Prevention Europe, the Organisation of European Cancer Institutes (OECI), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association for Cancer Research (EACR), the EuroTech Universities Alliance, the European Cancer Patient Coalition (ECPC), the European Academy of Cancer Sciences (EACS), and the European Society for Medical Oncology (ESMO); other organisations are expected to join shortly. Getting where we stand today required (a) building communities, (b) working in partnership, (c) engaging key stakeholders, (d) identifying champions among researchers, clinicians, policymakers and patients, (e) organizing science, and (f) providing future perspectives and evidence-based advice to inform policy (Celis and Heitor, 2019; Celis and Pavalkis, 2017) .
The EACS, as an independent organisation composed of eminent oncologists and cancer researchers, has actively supported the creation of a Cancer Mission (Adami et al., 2018) and, as a result, has been requested to coordinate the process of developing such a joint strategy to speak with a single voice. At a recent meeting organised by the EACS in Brussels, most of the organisations mentioned above met to prepare a short document addressing the goals, structuring activities and areas of priority required to accomplish the mission. The text, which was recently sent to the Cancer Mission Board, stated:
'To have impact on society at large, the Cancer Mission aims at uniting countries to substantially reduce the massive EU cancer burden and improve the quality of life of patients by promoting cost-effective, evidence-based best practices in cancer prevention, treatment, and care. Our goal is to achieve 10-year cancer survival for 3/4 patients by the year 2030. Because cancer mortality provides a more timely assessment of progress which also captures advances in primary prevention, it will be important to document the expected declining trends in age-standardized mortality in each EU country.
Achieving the goals will require: a Integrated, networked, and distributed infrastructures needed to reach the critical mass of resources, multidisciplinary expertise, technologies, data, patients and coordinated collaborative projects that are essential to promote science-driven and social innovations in the era of personalized (precision) cancer medicine , the EACR and the EACS. c Fostering networks of excellence for proof of concept trials and for clinical trials changing practice in prevention, therapeutics and outcomes research. This will require innovative proof of concept trials embedded in a high-quality translational research environment to discover the treatments of tomorrow. Attention should be given to rare cancers, comorbidities and specific clinical needs of particular patient groups (e.g. geriatric patients). Innovations generated by early prevention/clinical research must demonstrate added value before use by the healthcare/prevention organisations. For the final assessment of cost-effectiveness, outcomes research is required. d Establishment of a policy board to identify best strategies to implement activities effectively. Essential tasks include the analysis of funding mechanisms, organizing the science, addressing ethical issues, and the establishment of robust governance structures to achieve the set goals.
Areas of research priority:
a Fundamental and preclinical research: the engine that fuels innovation in prevention and therapeutics.
Fostering innovative research to identify new causes of cancer, to develop diagnostic markers for detecting premalignant disease, to elucidate the underlying mechanisms of drug and immunotherapy resistance and to identify therapeutic strategies to overcome these. b Primary cancer prevention: a pan-European programme (exposure and lifestyle focused). Cancer prevention and implementation research to be concentrated in networks with a wide geographical distribution. Identification of causes of cancer and methodologies to identify individuals at higher risk, combined with initiatives to reduce carcinogenic exposures and encourage a healthy lifestyle while offering equal access to active primary prevention (e.g. vaccination, medical prevention Establishment of EU-wide, shared databases providing access to standardised patient-derived data and genomic/molecular marker information from wearables. Development of AI paradigms for mining the data to identify new correlations (improvements in predicting response, relapse, and side effects). g Fostering preclinical and clinical research in paediatric cancer. Support the further development of a comprehensive pediatric oncology program by the pediatric oncology community represented by SIOP Europe'.
The document will be updated regularly as new organisations and infrastructures join the platform, and further information becomes available regarding governance and the portfolio of projects and activities.
